Cancer-associated thrombosis
Introduction
The association between malignancy and thrombosis dates back to the mid 1800's when Armand Trousseau first observed the thrombotic predilection of patients suffering from cancer. He astutely commented that “I have long been struck with the frequency with which cancer patients are affected with painful edema in the superior or inferior extremities, whether one or the other was the seat of cancer” [1]. This link between cancer and thrombosis has since been validated both in studies demonstrating a high rate of venous thromboembolic events in patients suffering from cancer and in the 3–25% of individuals who present with an unprovoked thrombotic event and are later diagnosed with cancer within two years [2], [3], [4], [5].
Almost one in five cases of all symptomatic deep venous thrombosis are thought to be cancer-related [6]. There is limited prospective data assessing the incidence of venous thromboembolic events in cancer patients through systematic screening and thus most estimates regarding the frequency of events are derived from autopsy series, epidemiologic surveys, and prospective chemotherapeutic trials. The prevalence of thrombosis in autopsy series ranges from 10 to 20% [7], [8], [9]. Among residents of Olmsted County, individuals diagnosed with cancer experienced a 4.1-fold increased risk of venous thromboembolic events compared to the general population—a risk that increased an additional 2-fold following the administration of chemotherapy [10]. Thrombosis is a well-recognized complication of specific chemotherapeutics such as anti-estrogens [11], [12], [13], [14] and several anti-angiogenic agents [15], [16]. For instance, approximately 25% of patients with myeloma treated with thalidomide in combination with either dexamethasone or chemotherapy suffer a venous thromboembolic event [17], [18], [19]. Thrombosis also commonly complicates surgery whereby nearly one-quarter of individuals who undergo surgery for cancer demonstrate venographic evidence of deep vein thrombosis postoperatively [20], [21].
The risk of thrombosis attributed to the malignant state also is not uniform across all forms of cancer. In a large autopsy series of 6197 cancer patients, pulmonary embolism was apparent in 34.5% of 55 patients with ovarian cancer but none of the 38 patients with head or neck cancer [7]. Levitan et al. analyzed the discharge diagnosis for 1,211,944 Medicare patients diagnosed with cancer and hospitalized between 1988 and 1990. Similar to the autopsy findings, they noted almost a 10-fold greater rate of venous thromboembolic events among patients suffering from ovarian, brain, and pancreatic cancers compared to those with head or neck cancer [22]. In a recent record linkage study that compared data from a cancer registry in the Netherlands with a clinical anticoagulation database, the cumulative incidence of venous thromboembolic events was highest for pancreatic, brain, ovarian, and bone malignancies [23]. The preliminary results of two prospective trials investigating the efficacy of prophylactic anticoagulation in breast and lung cancer patients were recently reported [24]. Deep vein thrombosis was diagnosed by screening duplex ultrasonography in 4% of patients. With strong evidence linking deep vein thrombosis and malignancy there has been considerable interest in understanding the molecular basis for thrombosis in cancer patients and identifying hemostatic markers most predictive of thrombosis.
Section snippets
Hemostatic markers
A number of studies published have detailed the laboratory abnormalities apparent in patients with malignancy. These include the shortening of the activated partial thromboplastin time, elevated levels of coagulation proteins (fibrinogen, factors V, VIII, IX, and XI), thrombocytosis, elevated fibrin/fibrinogen degradation products, and an accelerated rate of fibrinogen turnover [25], [26], [27], [28], [29], [30], [31], [32], [33], [34]. However, these laboratory measurements have not proven
Molecular basis for thrombosis
Several substances elaborated by malignant cells have been identified that can activate the blood coagulation cascade. These include cytokines, a cysteine protease, tissue factor, and microparticles bearing tissue factor.
Catheter-related thrombosis
Central venous access catheters are commonly utilized in cancer patients for the delivery of blood products and chemotherapy. In prospective studies, the incidence of thrombosis as detected by venography is between 32 and 66% [130], [131]. Direct endothelial irritation is thought to play a major role in catheter thrombosis although catheter-specific risk factors have also been identified, including insertion site, technique, and material. A prospective study which enrolled 85 children with
Chemotherapy-induced thrombosis
Chemotherapy has been implicated in contributing to the hypercoagulability of malignancy. The overall annual incidence of deep venous thrombosis in patients treated with chemotherapy is about 11% [137]. Different regimens and classes of chemotherapeutics carry different thrombotic risks, a problem that has become particularly apparent with the advent of several anti-angiogenic agents. The mechanisms underlying the hypercoagulability are not understood.
Khorana et al. recently reported the
Hereditary thrombophilia
Hereditary risk factors are associated with VTE. These include Factor V Leiden and prothrombin G20210A gene mutation which carry a 3- to 8-fold increased risk of thrombosis in outpatients who present with an idiopathic VTE. While malignancy alone is clearly a risk factor for thrombosis, the additional influence of such hereditary thrombophilic risk factors has been difficult to distinguish. In a large case-control study, carriers of Factor V Leiden with malignancy were 12 times more likely to
Conclusion
Although progress has been made in developing anticoagulant strategies for the management of thromboembolic disease in cancer patients, VTE remains a leading cause of death in cancer patients. With the advent of several anti-angiogenic agents clearly associated with thrombotic complications, there is now a renewed sense of urgency in the field. The interplay of chemotherapeutics, tumor cells, endothelium, and circulating procoagulants in promoting thrombus formation is under investigation, but
Reviewers
Dr. Kenneth A. Bauer, Director Thrombosis Clinical Research, Beth Israel Deaconess Medical Center, Department of Medicine - Hematology, Oncology, 330 Brookline Avenue, Boston, MA 02215, United States
Dr. Frederiek van Doormaal, Academic Medical Center, Vascular Medicine, Meibergdreef 9, Amsterdam 1105 AZ, Netherlands
Dr. Bruce Furie (Professor): Dr. Furie's research interests focus within the area of hemostasis and thrombosis. Major activities in the laboratory involve the study of the structure-function relationships of the blood coagulation proteins, with special attention directed toward the vitamin K-dependent proteins, and the assembly of Factor IX and Factor VIII on membrane surfaces. In addition, his laboratory discovered P-selectin, and the study of vascular cell adhesion molecules has been a
References (152)
Malignancy, thrombosis and Trousseau: the case for an eponym
J Thromb Haemost
(2003)- et al.
Screening for occult cancer in patients with acute deep vein thrombosis or pulmonary embolism
J Thromb Haemost
(2004) - et al.
Overview of the main outcomes in breast-cancer prevention trials
Lancet
(2003) - et al.
Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy
Blood
(2002) - et al.
Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy
Blood
(2001) - et al.
Incidence of venous thrombosis in a large cohort of 66, 329 cancer patients: results of a record linkage study
J Thromb Haemost
(2006) - et al.
Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway
J Thromb Haemost
(2004) - et al.
Haemostatic abnormalities in lung cancer: prognostic implications
Eur J Cancer
(1997) - et al.
Effect of human recombinant cytokines on the induction of macrophage procoagulant activity
Blood
(1994) - et al.
Tumor necrosis factor induces tissue factor-like activity in human leukemia cell line U937 and peripheral blood monocytes
Blood
(1988)
Induction of tissue factor-like activity of human monoblastic leukemia cell line by tumor necrosis factor-alpha
Thromb Res
C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor
Blood
Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis
Lancet
Risk factors for catheter-related thrombosis in cancer patients
Eur J Cancer
Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment
J Thromb Haemost
Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE)
Am J Med
Deficiency of von Willebrand factor-cleaving protease activity in the plasma of malignant patients
Thromb Res
Cancer procoagulant A: a factor X activating procoagulant from malignant tissue
Thromb Res
Activation of blood coagulation and the activity of cancer procoagulant (EC 3.4. 22. 26) in breast cancer patients
Cancer Lett
Factor X-activating activity in normal and malignant colorectal tissue
Thromb Res
Properties of proteins in cancer procoagulant preparations that are detected by anti-tissue factor antibodies
Arch Biochem Biophys
Coagulant and fibrinolytic activities in the leukemic cell lysates
Thromb Res
Potential role of interleukin-1 as the trigger for diffuse intravascular coagulation in acute nonlymphoblastic leukemia
Am J Med
Vascular endothelial cell growth factor-induced tissue factor expression in endothelial cells is mediated by EGR-1
Blood
Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis 10.1182/blood-2004-05-2042
Blood
Association of tissue-factor upregulation in squamous-cell carcinoma of the lung with increased tissue factor in circulating blood
Lancet Oncol
Tissue specific expression and serum levels of human tissue factor in patients with urological cancer
Cancer Lett
Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation
Blood
Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity
J Biol Chem
Platelet-derived microparticles express high affinity receptors for factor VIII
J Biol Chem
Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity
J Biol Chem
Human cell-derived microparticles promote thrombus formation in vivo in a tissue factor-dependent manner
J Thromb Haemost
Induction of microparticle- and cell-associated intravascular tissue factor in human endotoxemia
Blood
Cellular origin and procoagulant properties of microparticles in meningococcal sepsis
Blood
Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes
Blood
Circulating platelet-derived microparticles with procoagulant activity may be a potential cause of thrombosis in uremic patients
Kidney Int
Deep-vein thrombosis and the incidence of subsequent symptomatic cancer
N Engl J Med
The incidence of occult cancer in patients with deep venous thrombosis: a prospective study
J Intern Med
Undiagnosed malignancy in patients with deep vein thrombosis: incidence, risk indicators, and diagnosis
Cancer
Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study
Arch Intern Med
Prevalence of pulmonary embolism at necropsy in patients with cancer
J Clin Pathol
Causes of death in cancer patients
J Med
Observations on the developmental patterns and the consequences of pancreatic exocrine adenocarcinoma. Findings of 154 autopsies
Arch Surg
Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study
Arch Intern Med
First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial
Lancet
Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
J Natl Cancer Inst
Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group
J Clin Oncol
Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas
Clin Cancer Res
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer
J Clin Oncol
Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation
Br J Haematol
Cited by (146)
Tumor-educated platelets
2024, Clinica Chimica ActaPrimary prevention of cancer-associated venous thrombosis: Rationale and challenges in clinical practice
2023, Current Research in Translational MedicineImplementation of an electronic medical record tool for early detection of deep vein thrombosis in the ambulatory oncology setting
2019, Research and Practice in Thrombosis and HaemostasisThe role of neutrophils in thrombosis
2018, Thrombosis ResearchCitation Excerpt :Although this system is usually in a quiescent state, it is rapidly activated upon vascular injury and leads to the generation of a thrombus [1]. Since thrombotic events can be fatal (secondary to myocardial infarction, stroke) [2,3], a better understanding of the cellular and molecular events governing this process is crucial for the development of novel therapeutic approaches. In 1856, Virchow first enumerated the three predisposing factors contributing to thrombosis: blood hypercoagulability, stasis and vessel wall abnormalities (Virchow's triad; Fig. 1).
Dr. Bruce Furie (Professor): Dr. Furie's research interests focus within the area of hemostasis and thrombosis. Major activities in the laboratory involve the study of the structure-function relationships of the blood coagulation proteins, with special attention directed toward the vitamin K-dependent proteins, and the assembly of Factor IX and Factor VIII on membrane surfaces. In addition, his laboratory discovered P-selectin, and the study of vascular cell adhesion molecules has been a central theme of the laboratory. This group has developed novel instrumentation for real time in vivo confocal and widefield imaging of thrombus formation in the microcirculation of a living mouse. This work has attracted considerable attention because of the opportunity that it affords to study a complex physiologic system – blood coagulation and thrombosis – in a living animal. Dr. Bruce Furie was the recipient of the William Dameshek Prize of the American Society of Hematology in 1984. He was the recipient of a MERIT Award from the NIH and an honorary degree from Lund University in 2003. Dr. Furie is a co-editor of the hematology textbook, Hematology: Basic Principles and Practice and lead editor of Clinical Hematology–Oncology: Presentations, Diagnosis and Treatment. He serves as the President of the 2009 Congress of the International Society for Thrombosis and Haemostasis.
Dr. Barbara C. Furie (Professor): Interested in the posttranslational processing of blood clotting proteins, she has made major contributions to our knowledge of the molecular basis of γ-carboxylation and of the role of γ-carboxyglutamic acid in the calcium binding properties of the vitamin K-dependent blood clotting proteins. Her current work includes the study of the mechanism of action of the vitamin K-dependent carboxylase and its interaction with vitamin K. She has completed the structure of prothrombin bound to phosphatidylserine, thus contributing to our understanding of the assembly of blood coagulation complexes on membrane surfaces. The laboratory has used both NMR spectroscopy and X-ray crystallographic techniques. Dr. Furie has served on the Hematology Study Section of the NIH for which she was Chairperson. Dr. Furie was the recipient of the William Dameshek Prize of the American Society of Hematology in 1984 and an Outstanding Investigator Award from the International Society of Thrombosis and Hemostasis. She was a recipient of a MERIT Award from the NIH, an honorary degree from Lund University in 2003, and served on the Editorial Board of Blood. She has been a critical female role model for woman postdoctoral fellows. She also serves as the President of the 2009 ISTH Congress.